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Hypertriglyceridemia in patients with chronic renal failure: ceridemia in healthy individuals, results in endothelial
Possible mechanisms. Cardiovascular disease (CVD) is a major dysfunction [4]. Hypertriglyceridemia is a common phe-
cause of mortality in patients with chronic renal failure (CRF)
nomenon in CRF, introducing another factor for thecaused by numerous factors defined as traditional and uremia-
occurrence of endothelial dysfunction. In the next sectionsrelated risk factors. One of these risk factors, dyslipidemia, is
often observed in patients with CRF, resulting in abnormal we will primarily focus on the different metabolic path-
concentrations and composition of plasma lipoproteins. The ways that might contribute to altered lipid metabolism,
prominent features of uremic dyslipidemia are an increase in
resulting in the observed dyslipidemia in CRF.plasma triglycerides and cholesterol in nearly all lipoproteins,
and a reduction in high-density lipoprotein (HDL) cholesterol.
Because of its direct contact with the circulating blood, the
endothelium is preferentially subjected to the modulatory ef- LIPID METABOLISM IN CRF
fects of these altered lipoproteins. Little is known about the
Renal insufficiency is associated with abnormal con-mechanisms for hypertriglyceridemia in CRF.
centrations and composition of plasma lipoproteins. TheThis review highlights several studies over the past years
that have contributed to knowledge of hypertriglyceridemia, lipid abnormalities are characterized by an increase in
especially in combination with renal diseases and their dialysis plasma triglycerides and cholesterol in nearly all lipopro-
treatment. The underlying mechanisms behind hypertriglyceri-
teins (VLDL, IDL, and LDL), whereas HDL cholesteroldemia have not been fully clarified and may indeed be multifac-
is reduced [5, 6]. Dyslipidemia becomes more pronouncedtorial. Hypertriglyceridemia may contribute to the progression
of atherosclerosis. Therefore, it is essential to study the putative as renal failure advances and becomes aggravated when
mechanisms for uremic dyslipidemia, since optimal treatment patients start renal replacement therapy.
is essential for the prevention or delay of cardiovascular com-
Hemodialysis (HD), as well as peritoneal dialysis (PD),plications in patients with CRF.
can both provide adequate relief of uremic symptoms,
but the dialysis techniques appear to have differential
effects on uremic dyslipidemia [5, 6]. Plasma concentra-Nowadays, it is well known that cardiovascular disease
tion of apoB100 is increased in PD patients, whereas a(CVD) is a major cause of mortality in patients with
normal concentration of apoB100 is found in HD pa-chronic renal failure (CRF). The incidence of CVD in
CRF accounts for 40% to 50% of deaths among patients tients [6]. The increase in apoB100 is mostly markedly
on renal replacement therapy [1]. Risk factors for CVD in the VLDL fraction and to a minor extent for IDL
can be divided in traditional and uremia-related factors and LDL [6]. Studies have shown that long-term treat-
[1, 2]. It is important to note that most of these risk ment with CAPD may further deteriorate some of the
factors are associated with endothelial dysfunction, lipoprotein abnormalities [7, 8]. Although lipid profiles
which is almost invariably present in CRF [3] and may differ between PD and HD, it is possible that abnormali-
be the common link between risk factors and CVD. ties in triglyceride metabolism might have some similari-
In literature, abundant evidence is present, showing ties in the pathogenesis of atherosclerosis and endothe-
that hypertriglyceridemia, as well as postprandial trigly- lial dysfunction in these groups. In the next section, we
will primarily focus on the possible mechanisms that
could contribute to the observed increase in the poolKey words: renal insufficiency, dialysis, apoB100, VLDL, free fatty
acids. size of triglycerides and apoB100 found in the VLDL
fraction. 2003 by the International Society of Nephrology
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Fig. 1. Simplified models concerning different
metabolic pathways. Shown are the pathways
for triglyceride synthesis in normal subjects (A),
and in patients with CRF (B). Abbreviations
are: FFA, free fatty acids; hSL, hormone sen-
sitve lipase; TG, triglycerides; LPL, lipoprotein
lipase.
PROPOSED MECHANISMS FOR as induce conformational changes of the apoB100 pro-
HYPERTRIGLYCERIDEMIA IN CRF tein, resulting in altered binding to the receptors and
clearance of the particles. Although the above mentionedUntil now, little has been known about the mecha-
studies were done under fasting conditions, it is alsonisms for hypertriglyceridemia in dialysis patients. Sev-
proposed that in the postprandial period the presenceeral studies describe triglyceride or apoB turnover in
of chylomicron remnants is increased in patients withdialysis patients [9–11], and an impaired triglyceride re-
CRF, resulting in endothelial dysfunction. Evidence formoval is often proposed as the cause of hypertriglyceri-
disturbed remnant clearance was given by the study ofdemia in predialysis patients, as well as in patients on
Weintraub et al [11], showing a severe defect in the clear-dialysis. Additionally, two studies suggest the involve-
ance of chylomicrons in patients with CRF. To summa-ment of an increased triglyceride synthesis rate [9] or
rize, it is reasonable to believe that disturbances areVLDL apoB100 overproduction [10]. Care must be taken
present in VLDL catabolism and synthesis both. Today,in interpreting Chan’s data, since the hyperlipidemic
the mechanisms contributing to the observed hypertri-patient group was not homogenous (HD-, PD-, and dia-
glyceridemia are still under debate, since no direct evi-betic patients), reflecting non-common underlying mech-
dence is present. The pathways that could contribute toanisms. It is important to know that in the above men-
the hypertriglyceridemia are shown in Fig. 1B and willtioned studies, exogenous labeling (125I) was used, which
may affect triglyceride clearance of the particles, as well be discussed below.
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INCREASED VLDL-1 AND/OR VLDL-2 ent in patients with CRF, since it is known that the major
APOB100 PRODUCTION site of insulin resistance resides in peripheral tissues, and
not in liver [17].Most studies concerning lipid metabolism in patients
with CRF have measured total VLDL pool size, although
it would be more informative to subdivide this lipopro- DE NOVO LIPOGENESIS
tein fraction into VLDL-1 (triglyceride-rich VLDL) and
Alternatively, fatty acids needed for VLDL apoB se-VLDL-2 (triglyceride-poor VLDL). In healthy subjects,
cretion could also be derived from de novo lipogenesisacute hyperinsulinemia lowers plasma triglycerides and
(DNL, formation of fatty acids using glucose as sub-VLDL levels, principally by suppressing VLDL-1 apoB-
strate). A high carbohydrate intake could increase DNL.100 production, but not VLDL-2 apoB100 production
It is, therefore, tempting to speculate that, despite a[12]. This indicates that apoB100 production rate of
different rate of glucose administration, extensive glu-VLDL-1 and VLDL-2 is independently regulated. Suth-
cose loading during PD could increase DNL. This mayerland et al [13] reported that endogenous cholesterol
result in increased FFA availability that might subse-synthesis might be linked to VLDL apoB metabolism.
quently stimulate VLDL apoB100 secretion (Fig. 1B,Recently, we have shown that endogenous cholesterol
pathway C). Different groups are still debating aboutsynthesis (determined by lathosterol/cholesterol ratio) is
the importance of this pathway, since conclusions werestrongly associated with the rate of VLDL-2 apoB100
based on indirect evidence. Little et al [8] found nosecretion (abstract; Prinzen BHCMT, Circulation 106:19,
correlation with aspect of treatment such as glucose load,2002) (Fig. 1A, pathway A). In patients with hypertri-
whereas Faller et al [7] suggested an adaptive processglyceridemia or insulin resistance VLDL-1, apoB100
with an initial rise in serum triglycerides related to glu-production is increased [14]. VLDL-2 apoB100 is over-
cose load. Recently, we directly measured the contribu-produced in patients with increased total cholesterol [15]
tion of DNL to total FFA availability in PD patientsand in patients with proteinuria [16]. In CRF patients,
and control subjects using stable isotope techniques andreduced insulin sensitivity, protein loss, as well as an
observed that DNL was normal (below 5%) in bothincrease in cholesterol are frequently observed [5, 17],
groups (unpublished data). These data indicate thatsuggesting that overproduction of both VLDL-1 and
DNL is not a major pathway contributing to the observedVLDL-2 apoB100 may occur (Fig. 1B, pathway A). To
hypertriglyceridemia.summarize, overproduction of VLDL-1 apoB100 and
VLDL-2 apoB100 observed in patients with CRF is most
likely the result of different metabolic routes. These tri- LIPOPROTEIN LIPASE AND HEPATIC LIPASE
glyceride-rich apoB100 containing particles are delipi-
Several authors have suggested that the primary meta-dated and will eventually result in the atherogenic small
bolic defect appears to be a defective catabolism of tri-dense LDL or buoyant dense LDL that may contribute
glyceride rich lipoproteins (primarily VLDL) by the en-to progression of atherosclerosis.
zymes lipoprotein lipase (LPL) and hepatic lipase (HL)
(Fig. 1B, pathway D). LPL-mediated lipolysis is stimu-
FFA AVAILABILITY lated by apoCII and inhibited by apoCIII. In uremic pa-
tients, postheparin plasma LPL activity and HL activityIt has been suggested that increased free fatty acids
have been reported to be normal or reduced [5, 18],(FFA) availability from peripheral tissues (muscle and
while the apoCII/apoCIII ratio is decreased. A possibleadipose tissue) could be of major importance in de-
disturbance in both enzymes, accompanied by an increasetermining hypertriglyceridemia. The release of FFA
in apoCIII in VLDL [6], results in a prolonged half-lifefrom muscle and adipose tissue primarily by hormone
sensitive lipase (hSL) is controlled by insulin (Fig. 1A, of the VLDL particles, which may explain the observed
pathway B). A marked reduction in insulin sensitivity hypertriglyceridemia in these patients.
in peripheral tissues where hSL is expressed results in
increased FFA availability from muscle and adipose tis-
PERITONEAL PROTEIN LOSSsue. The increased FFA availability could subsequently
Finally, another underlying mechanism may be relatedstimulate the production of apoB100-containing lipopro-
to the loss of large molecular weight substances in theteins (Fig. 1B, pathway B). In type 2 diabetics [14], insulin
PD fluid. The protein losses across the peritoneal mem-is not able to acutely inhibit the release of VLDL-1
brane can be considerable, ranging from 5 to 15 g/day.apoB100, despite efficient suppression of plasma FFA,
Because it has been shown that urinary albumin loss insuggesting that a component of insulin resistance is the
nephrotic syndrome results in enhanced hepatic proteinfailure of the liver to suppress the release of triglyceride-
and lipoprotein synthesis [19, 20], it has been suggestedrich VLDL, rather than an increased FFA availability.
However, it is questionable if such a mechanism is pres- that peritoneal protein losses may be responsible for
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of L-arginine does not improve arterial endothelial function inhyperlipidemia via a similar mechanism [5]. Until now,
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